172 related articles for article (PubMed ID: 25368217)
1. Diabetes management: More than just cardiovascular risk?
Zimmerman RS; Pantalone KM
Cleve Clin J Med; 2014 Nov; 81(11):672-6. PubMed ID: 25368217
[No Abstract] [Full Text] [Related]
2. Implications of thiazolidinedione use and cardiovascular risk: is it all about the sugar?
Krantz MJ
Pharmacotherapy; 2006 Jul; 26(7):1049; discussion 1049-50. PubMed ID: 16803430
[No Abstract] [Full Text] [Related]
3. Glycemic management of type 2 diabetes: how tight is right and how to get there.
Nathan DM
Arch Intern Med; 2008 Oct; 168(19):2064-6. PubMed ID: 18955633
[No Abstract] [Full Text] [Related]
4. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo.
Calle-Pascual A; Garcia-Honduvilla J; Martin-Alvarez PJ; Calle JR; Maranes JP
Diabetes Metab; 1996 Jun; 22(3):201-2. PubMed ID: 8697309
[No Abstract] [Full Text] [Related]
5. Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.
Spallarossa P; Barsotti A; Cordera R; Ghigliotti G; Maggi D; Brunelli C
J Endocrinol Invest; 2004 May; 27(5):485-95. PubMed ID: 15279085
[TBL] [Abstract][Full Text] [Related]
6. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes.
Meerwaldt R; Links T; Zeebregts C; Tio R; Hillebrands JL; Smit A
Cardiovasc Diabetol; 2008 Oct; 7():29. PubMed ID: 18840258
[TBL] [Abstract][Full Text] [Related]
7. [Diabetics' life is about one third shorter. So you improve the prognosis of these high-risk patients].
Stiefelhagen P
MMW Fortschr Med; 2003 Apr; 145(15):18, 20. PubMed ID: 15104261
[No Abstract] [Full Text] [Related]
8. Commentary: the PROactive study--the glass is half full.
Fonseca V; Jawa A; Asnani S
J Clin Endocrinol Metab; 2006 Jan; 91(1):25-7. PubMed ID: 16303829
[No Abstract] [Full Text] [Related]
9. [Glitazones critically evaluated].
Schernthaner G
Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
[No Abstract] [Full Text] [Related]
10. [Type 2 diabetic as cardiovascular risk patient].
Krankenpfl J; 2005; 43(4-6):106. PubMed ID: 16171052
[No Abstract] [Full Text] [Related]
11. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Veneman TF
Ned Tijdschr Geneeskd; 2006 Apr; 150(16):931-2; author reply 932-3. PubMed ID: 16686096
[No Abstract] [Full Text] [Related]
12. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
[TBL] [Abstract][Full Text] [Related]
13. [Too positive comment on glitazones].
Lindberg M
Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
[No Abstract] [Full Text] [Related]
14. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Heine RJ
Ned Tijdschr Geneeskd; 2006 Apr; 150(16):930-1; author reply 932-3. PubMed ID: 16686095
[No Abstract] [Full Text] [Related]
15. From the World Congress of Cardiology, Barcelona, 2006--Support for wider metformin usage in type 2 diabetes.
Cardiovasc J S Afr; 2006; 17(5):267. PubMed ID: 17117236
[No Abstract] [Full Text] [Related]
16. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
Szymborska-Kajanek A; Strojek K
Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
[No Abstract] [Full Text] [Related]
17. From hyperglycemia to the risk of cardiovascular disease.
Leiter LA
Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875
[TBL] [Abstract][Full Text] [Related]
18. [25 years of diabetic treatment by oral hypoglycemic agents: successes and failures].
Tattersall RB
Journ Annu Diabetol Hotel Dieu; 1984; ():183-91. PubMed ID: 6443219
[No Abstract] [Full Text] [Related]
19. Beta-glucans in the treatment of diabetes and associated cardiovascular risks.
Chen J; Raymond K
Vasc Health Risk Manag; 2008; 4(6):1265-72. PubMed ID: 19337540
[TBL] [Abstract][Full Text] [Related]
20. How important is diabetes as a risk factor for cardiovascular and other diseases in older adults?
Kengne AP; Patel A
PLoS Med; 2006 Oct; 3(10):e424. PubMed ID: 17048981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
